Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81c150af8961fd5ae4f74c3565019f3d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-20 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-815 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-461 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71 |
filingDate |
2006-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2011-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7040c7572871e94b0ea4c81e8bdb9482 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a244e8cc941629b2e6d882eaca6326a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbace514624916bd967e341502383412 |
publicationDate |
2011-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
ES-2353674-T3 |
titleOfInvention |
UNION FACTORS OF INSULIN-SIMILAR GROWTH FACTOR II (IGF-II). |
abstract |
A mutant IGF-II binding domain comprising the amino acid sequence of residues 1511 to 1650 of human IGF2R with less than 50 of said mutated residues, in which E1544 is substituted by a non-acidic amino acid residue that is different from N, P or G and; wherein said binding domain of mutant IGF-II binds to IGF2 with increased affinity with respect to residues 1511 to 1650 of human IGF2R. |
priorityDate |
2005-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |